Literature DB >> 17432690

[Clinical observation on effect of compound Shiwei Tablet in treating urinary tract infection].

Yong-li Zhan1, Xiu-ying Li, Sheng-xian Wu.   

Abstract

OBJECTIVE: To evaluate the safety and efficacy of Compound Shiwei Tablet (CST) in treating upper and lower urinary tract infection (UTI, pyretic stranguria of dampness-heat of the Lower-jiao type in 'TCM).
METHODS: A multi-center, randomized, and opened clinical trial was conducted in the UTI patients with Sanjin Tablet (ST) as the parallel positive control medicine. The comprehensive efficacy, effect on TCM syndrome score, and change of urinary leukocyte count were observed, and the adverse reaction was recorded.
RESULTS: In the 147 upper UTI cases and the 312 lower UTI cases after treatment, the comprehensive effect was higher and urinary leukocyte was less in the CST treated patients than in the ST treated patients (P < 0.05); but significant difference in the improvement of TCM symptoms was found between them only in the lower UTI cases ( P < 0.05); and no adverse reaction was observed during the treatment course.
CONCLUSION: CST has definite therapeutic efficacy on UTI and is safe in clinical application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432690

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

Review 1.  Chinese herbal medicine for treating recurrent urinary tract infections in women.

Authors:  Andrew Flower; Li-Qiong Wang; George Lewith; Jian Ping Liu; Qing Li
Journal:  Cochrane Database Syst Rev       Date:  2015-06-04

2.  Standardised Chinese herbal treatment delivered by GPs compared with individualised treatment administered by practitioners of Chinese herbal medicine for women with recurrent urinary tract infections (RUTI): study protocol for a randomised controlled trial.

Authors:  Andrew Flower; Kim Harman; George Lewith; Michael Moore; Felicity L Bishop; Beth Stuart; Nicholas Lampert
Journal:  Trials       Date:  2016-07-27       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.